By Fineline Cube 
Legend Biotech Corporation (NASDAQ: LEGN) reported first-quarter 2026 revenue of USD 305 million, representing 56% year-over-year growth, primarily driven by strong Carvykti (cilta-cel) sales performance and a USD 55 million milestone payment from Johnson & Johnson.
Financial Performance Overview
| Metric | Q1 2026 | Q1 2025 | YOY Change |
|---|---|---|---|
| Total Revenue | USD 305 million | USD 195.5 million* | +56% |
| Collaboration Revenue | USD 298.4 million | USD 185.6 million | +60.8% |
| License Revenue | USD 6.7 million | USD 9.4 million | -28.7% |
| Carvykti Net Trade Sales | USD 597 million | USD 368 million* | +62% |
*Calculated based on provided data
Carvykti Commercial Performance
Global Sales Breakdown
The CAR-T therapy co-developed with Janssen Biotech (Johnson & Johnson) demonstrated exceptional commercial momentum:
| Region | YOY Growth | Contribution to Total Growth |
|---|---|---|
| U.S. Market | +36% | Primary established market |
| Ex-U.S. Markets | +222% | Major growth driver, indicating rapid international expansion |
Commercial Trajectory
- Annualized run rate: Current quarterly sales suggest ~USD 2.4 billion annual Carvykti revenue
- Market penetration: Continued adoption in multiple myeloma indication across global markets
- Pricing stability: Strong net trade sales indicate maintained premium pricing despite competitive pressures
Revenue Stream Analysis
Collaboration Revenue Growth (+60.8%)
The USD 112.8 million increase in collaboration revenue was primarily driven by higher Carvykti sales under the Janssen partnership agreement, reflecting:
- Royalty escalators: Higher sales tiers triggering increased royalty rates
- Manufacturing margins: Potential contribution from Legend’s manufacturing activities
- Commercial milestone recognition: Ongoing revenue recognition from commercial achievements
License Revenue Decline (-28.7%)
The USD 2.7 million decrease in license revenue was attributed to the Novartis Pharma AG agreement, where:
- Revenue recognition timing: Revenue recognized over time as Phase I study for LB2102 progresses
- Development stage impact: Lower recognition rate during early clinical phases
- Contract structure: Milestone-based payments versus upfront recognition
Strategic Partnership Highlights
Johnson & Johnson Milestone
- Recent payment: USD 55 million milestone payment received last month from J&J
- Partnership validation: Demonstrates continued commitment to Carvykti commercial success
- Financial impact: Contributes to strong cash position and reduced funding requirements
Novartis Collaboration Status
- Program: LB2102 in Phase I development
- Therapeutic area: Details not disclosed in earnings release
- Revenue model: Time-based recognition reflecting development progress
Market Context & Competitive Positioning
CAR-T Market Dynamics
- Multiple myeloma leadership: Carvykti maintains strong position in BCMA-targeted CAR-T segment
- International expansion: 222% ex-U.S. growth indicates successful market access strategies
- Competitive landscape: Facing competition from other BCMA therapies but maintaining differentiation through efficacy profile
Financial Strength Indicators
- Self-sustaining model: Strong collaboration revenue reduces need for equity financing
- Cash generation: Operating cash flow likely positive given revenue scale
- Investment capacity: Financial strength enables continued pipeline investment beyond Carvykti
Forward Outlook Considerations
- Carvykti sustainability: Continued strong growth trajectory dependent on market penetration and competitive dynamics
- Pipeline development: Resources available to advance internal programs alongside partnered assets
- Geographic expansion: Ex-U.S. growth suggests significant untapped market opportunity
- Partnership leverage: J&J relationship provides global commercial infrastructure and regulatory expertise
The Q1 results demonstrate Legend Biotech’s successful transition from development-stage company to commercial-stage biopharmaceutical leader, with Carvykti establishing itself as a major revenue generator in the global oncology market.
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, commercial growth, and partnership outcomes. Actual results may differ due to risks including competitive pressures, regulatory changes, and market dynamics.-Fineline Info & Tech